Azaindoles for inhibiting aurora2 and other kinases

Details Azaindoles for inhibiting aurora2 and other kinases Azaindoles for inhibiting aurora2 and other kinases

2011-05-17

2011-05-17

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S350000

Reexamination Certificate

active

07943616

ABSTRACT:
The invention is directed to physiologically active compounds of general formula (I):—and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

REFERENCES:
patent: 3524860 (1970-08-01), Albertson et al.
patent: 3992392 (1976-11-01), Gassman
patent: 5338849 (1994-08-01), Festal
patent: 5521213 (1996-05-01), Prasit
patent: 5681959 (1997-10-01), Bishop
patent: 5714495 (1998-02-01), Viaud
patent: 6025366 (2000-02-01), Walsh
patent: 6169091 (2001-01-01), Cockerill
patent: 6207669 (2001-03-01), Cockerill
patent: 6232320 (2001-05-01), Stewart
patent: 6348487 (2002-02-01), Connor
patent: 6384235 (2002-05-01), Henkelmann
patent: 6387900 (2002-05-01), Pevarello
patent: 6407259 (2002-06-01), Harris
patent: 6770643 (2004-08-01), Cox et al.
patent: 7227020 (2007-06-01), Cox et al.
patent: 0405602 (1991-01-01), None
patent: 0509974 (1992-10-01), None
patent: 0557171 (1995-07-01), None
patent: 0716855 (1996-06-01), None
patent: 0737685 (1996-10-01), None
patent: 1085950 (2001-03-01), None
patent: 2298199 (1996-08-01), None
patent: 06-247966 (1994-09-01), None
patent: WO95/10513 (1995-04-01), None
patent: WO96/06840 (1996-03-01), None
patent: WO98/06703 (1998-02-01), None
patent: WO98/22457 (1998-05-01), None
patent: WO 9836035 (1998-06-01), None
patent: WO98/47899 (1998-10-01), None
patent: WO99/20624 (1999-04-01), None
patent: WO9945016 (1999-09-01), None
patent: WO99/51231 (1999-10-01), None
patent: WO99/51232 (1999-10-01), None
patent: WO99/51233 (1999-10-01), None
patent: WO99/51234 (1999-10-01), None
patent: WO99/51595 (1999-10-01), None
patent: WO 9951596 (1999-10-01), None
patent: WO99/58518 (1999-11-01), None
patent: WO00/17202 (2000-03-01), None
patent: WO00/40547 (2000-07-01), None
patent: WO 0147922 (2000-07-01), None
patent: WO0075117 (2000-12-01), None
patent: WO01/02369 (2001-01-01), None
patent: WO 01/30774 (2001-05-01), None
patent: WO01/47922 (2001-07-01), None
patent: WO01/53268 (2001-07-01), None
patent: WO01/60816 (2001-08-01), None
patent: WO01/62252 (2001-08-01), None
patent: WO01/72720 (2001-10-01), None
patent: WO01/79198 (2001-10-01), None
patent: WO01/96336 (2001-12-01), None
patent: WO02/10137 (2002-02-01), None
patent: WO02/22601 (2002-03-01), None
patent: WO02/22602 (2002-03-01), None
patent: WO02/22603 (2002-03-01), None
patent: WO02/22604 (2002-03-01), None
patent: WO02/22605 (2002-03-01), None
patent: WO02/22606 (2002-03-01), None
patent: WO02/22607 (2002-03-01), None
patent: WO02/22608 (2002-03-01), None
patent: WO 0228831 (2002-04-01), None
patent: WO03/000688 (2003-01-01), None
Liu et al, “Synthesis, Structures and Electroluminescence of New Blue/Green Luminescent Chelate Compounds . . . ” Journal of the American Chemical Society, vol. 122(15), pp. 3671-3678 (2000).
Bundgaard et al, “A Novel Solution-Stable, Water-Soluble Prodrug Type for Drugs Containing a Hydroxyl or an NH-Acidic Group” Journal of Medicinal Chemistry, vol. 32(12), pp. 2503-2507 (Dec. 1989).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Clark et al, “Preparation of pyrrolo[2,3-b]pyrazines and pyrazino[2,3-b]indole” Chemistry and Industry, vol. 5, pp. 215-216 (1975).
Martin et al, “Selective Reactions of o-chlorobenzonitrile: SNAr” Tetrahedron Letters, vol. 30(8), pp. 935-936 (1989).
U.S. Appl. No. 09/847,962, filed Jun. 2, 2001, Li.
Busev et al., Extraction-Photometric DeterminatIon of Molybdenum by Means of 6,7-Dihydroxy-2,4-Diphenylbenzopyrilium Chloride, Zhurn. Anallt. Khimii, vol. 16, pp. 571-577, 1961.
Clark. B. A. J. et al., Mass Spectrometry of Pyrrolo[2,3-b]pyrazines and Pyrazino[2,3-b]indole, Org. Mass Spectrom, vol. 12(7), pp. 421-423, 1977.
Clark, Bernard A. J. et al., Preparation of pyrrolo[2,3-b]pyrazines and pyrazino[2,3-b]indole, Chemistry and Industry (London), 1975, pp. 215-216.
Clark, Bernard A. J. et al., Formation of Certain Substituted 6H-Pyrrolo[2,3-b]pyrazines by Thermal Cyclisation of Pyrazinylhydrazones and a Route to 5H-Pyrazino[2,3-b]indole; a Synthesis of 6H-Pyrrolo[2,3-b]pyrazine and Some of Its Properties, Journal of Chemical Society, Perkin Transactions 1, vol. 1(13), pp. 1361-1363, 1976.
Davis, Michael L. et al., Reactions of beta-(Lithiomethyl)azines with Nitriles as a Route to Pyrrolo-pyridines, -quinolines, -pyrazines, -quinoxalines and -pyrimidines, Tetrahedron, vol. 48, No. 5, pp. 939-952, 1992.
Hands, David et al., A Convenient Method for the Preparation of 5-, 6- and 7-Azaindoles and Their Derivatives, Synthesis, Jul. 1996, pp. 877-882.
Hardy, Christopher R. et al., Ring Opening or Rearrangement versus N-Oxidation in the Action of Peracids upon Pyrrolo[2,3-b]pyridines, Pyrrolo[2,3-b]pyrazines, and Triazolo[1,5-a]- and Triazolo[4,3-a]-pyrazine. Some Chemical and Spectroscopic Properties of the Triazolopyrazines and Their N-Oxides, J.C.S., Perkin Trans. 1, pp. 506-511, 1980.
Henry, James R. et al., 6-amino-2(4-fluorophnyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo[2,3-b]pyrdine (RWY68364): A Potent and Selective p38 Kinase Inhibitor, J. Med. Chem., vol. 41, No. 22, 4196-4198, 1998.
Herbert, R. et al., 1H-Pyrrolo[2,3-b]pyridines. Part II. Fragmentation of Some 1H-Pyrrolo[2,3-b]pyridines Induced by Electron Impact, Journal of the Chemical Society Sect. B. Physical Organic, 1970, vol. 3, pp. 459-463.
Herbert, R. et al., Syntheses and Properties of 1H-Pyrrolo[2,3-b]pyridines, J. Chem. Soc., 1969, pp. 1505-1514.
Kruse, C. G. et al., Furo- and Thiano[2,3-b]pyrazines, Part 2. Chemical Properties of 2-Substituted Derivatives, Recueil des Travaux Chimiques des Paye-Bas; Journal of the Royal Netherlands Chemical Society, vol. 97(6), pp. 151-155, 1978.
Marot, Christophe et al., Pharmacophoric Search and 3D-QSAR Comparative Molecular Field Analysis Studies on Agonists of Melatonin Sheep Receptors, J. Med. Chem., vol. 41, No. 23, pp. 4453-4465, 1998.
Martin, par Christian et al., Reactions Selectives de L'O.Chlorobenzonitrile : SNAr, Tetrahedron Letters, vol. 30, No. 8, pp. 935-936, 1989.
Park, Sang Sun et al., A Facile Synthesis of 2,3-Disubstituted Pyrrolo[2,3-b]pyridines via Palladium-Catalyzed Heteroannulation with Internal Alkynes, Tetrahedron Letters, NL, Elsevier Science Publishers, vol. 39, No. 7, pp. 627-630, 1998.
Vierfond, par Jean-Michel et al., Cyclisation par Amination Intramoleculaire Dane la Serie de la Pyrazine, Tetrahedron Letters, vol. 22, No. 13, pp. 1219-1222, 1961.
Laura C. Cooper et al., 2-Aryl Indole NK, Receptor Antagonists: Optimisation of Indole Substitution, Bioorganic & Medicinal Chemistry Letters, (2001), pp. 1233-1236, vol. 13.

Affiliated with

Also associated with

Rating

Azaindoles for inhibiting aurora2 and other kinases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Azaindoles for inhibiting aurora2 and other kinases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azaindoles for inhibiting aurora2 and other kinases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2660131